Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), freeze-dried intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor vin. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is based in Taiyuan, China.
Metrics to compare | 000403 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship000403PeersSector | |
|---|---|---|---|---|
P/E Ratio | 27.3x | 31.6x | −0.6x | |
PEG Ratio | −0.85 | 0.29 | 0.00 | |
Price/Book | 1.9x | 2.7x | 2.6x | |
Price / LTM Sales | 6.4x | 7.0x | 3.3x | |
Upside (Analyst Target) | 32.2% | 17.5% | 43.2% | |
Fair Value Upside | Unlock | −0.5% | 7.0% | Unlock |